The concept of bioactive lipids and its utility for under standing cell and organismal biology has evolved over the past several decades, from studies on inositol phospho lipids in the 1950s to studies on prostaglandins in the 1960s and the discovery of the bioactivity of diacyl glycerol in the 1980s. This concept continues to gain considerable traction 1 . Bioactive lipids are functionally defined as lipid species, levels of which respond (acutely and/or tonically) to the action of specific stimuli. These lipids then regulate specific downstream effectors and targets. Thus, bioactive lipids are components of cellular regulatory circuits (such as signalling networks), which distinguishes them from other lipids that have structural and/or energetic functions.
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. Bioactive lipids are functionally defined as lipid species, levels of which respond (acutely and/or tonically) to the action of specific stimuli. These lipids then regulate specific downstream effectors and targets. Thus, bioactive lipids are components of cellular regulatory circuits (such as signalling networks), which distinguishes them from other lipids that have structural and/or energetic functions.
We now understand that lipid metabolism is highly regulated and complex whereby many stimuli and agents affect one or more enzymes. The resulting changes in levels of lipids influence specific responses. Given the large number and diversity of these bioactive lipids and lipid derived products (for example, diacyl glycerol, phosphatidic acid, the various phosphatidyl inositol phosphates, inositol trisphosphate, ceramides, sphingosine 1phosphate (S1P), sphingosine, choles terol derivatives, eicosanoids and leukotrienes, to name a few), it is indeed nearly impossible for the cell bio logist to understand any key cellular pathway without encountering one or more bioactive lipids. Yet, paradoxi cally, to the nonlipidologist, the universe of lipids, and especially sphingolipids, has been rather impenetrable owing to complexities in working with lipids at nearly all levels. Fortunately, important technological advances have enabled more researchers to study and probe pathways involving bioactive lipids (Supplementary information S1 (box)).
Sphingolipids represent one of the major classes of eukaryotic lipids. Historically, the first sphingolipids were isolated from brain in the late 19th century by Thudicum, who introduced the name 'sphingosin' after the Greek mythical creature, the Sphinx, in deference to "the many enigmas which it presented to the inquirer" (REF. 2 ). Biochemical and chemical approaches in the first part of the 20th century resulted in elucidation of the chemical structure of sphingosine, one of the major sphingoid bases, which are the founding blocks of all sphingolipids (distinguishing sphingolipids from other lipids). This discovery was followed by elucidation of the classes of complex sphingolipids (sphingomyelins and glycosphingolipids, including the gangliosides), which were appreciated as components of the plasma membrane and as modulators of cell-cell interactions and cell recognition. Concomitantly, sphingolipidoses -that is, defects in the metabolism of sphingolipids (details of which are shown in FIG. 1) -were discovered as lysosomal storage disorders in humans.
Studies in the mid1980s defined bioactive functions for sphingosine, followed by ceramide and S1P. These emerging roles in various aspects of cell growth regu lation catapulted sphingolipids into a verifiable class of bioactive lipids. The main bioactive sphingolipids (TABLE 1; Supplementary information S2 (table)) that have received the most attention are ceramide, sphingo sine and S1P. Additional evidence also implicates ceramide1phosphate (C1P), glucosylceramide, lacto sylceramide and some of the gangliosides as candidate bioactive lipids.
In this Review, we first present a brief background on bioactive sphingolipids and their metabolism, high lighting important progress made in the past decade. With several notable examples, we then illustrate the myriad physiological and pathophysiological roles of sphingolipids, providing evidence for their important functions in nearly all cell biological processes.
Sphingolipid metabolism
Bioactive sphingolipids are regulated by various enzymes and fluxes of different metabolites (FIG. 1) , with around 40 enzymes in mammals involved in their metabolism (Supplementary information S3 (table) ). These enzymes are the products of distinct genes, can occur as splice variants and can feature a plethora of posttranslational modifications, which affect their enzymatic activity and function. Key regulated enzymes in de novo synthesis and hydrolysis are discussed in BOXES 1 and 2, respectively. The reader is also directed to recent reviews that extensively discuss metabo lism of sphingolipids [3] [4] [5] . Critically, all key enzymes in sphingolipid metabolism have now been molecularly identified, which has revealed the vast complexity of these metabolic pathways and their precise subcellular compartmentalization.
In its most basic conceptualization (FIG . 1A; TABLE 1 ; Supplementary information S2 (table)), the universe of sphingolipids can be thought of as a discrete set of metabolically connected pathways initiated by the con densation of the amino acid serine and the lipid palmi tate. A set of enzymes then catalyses de novo synthesis, catabolism, recycling and interconversion of these lipids. Ultimately, the action of a lyase, acting on sphingoid base phosphates, provides the only known 'exit' from this network of sphingolipids (FIG. 1A) .
This molecular era has allowed deep investiga tion of the functions of enzymes (an 'enzymecentric approach') through the use of contemporary tools of biochemistry, molecular biology and genetics, which has complemented a 'lipidcentric approach' that focuses on defining the function of individual bioactive lipids (Supplementary information S1 (box)). Focusing on enzymes has allowed deeper investigation into how these enzymes are regulated (BOXES 1,2), which in turn is essential for understanding their activities as well as the activities of their products -the various sphingolipid species (see below).
The use of model organisms together with sphingo lipidomic and systems biology approaches also contrib utes to the dissection of the function and mechanisms of bioactive sphingolipids (Supplementary information S1 (box)). Importantly, mutations underlying various dis eases have been found in several genes for enzymes of sphingolipid metabolism 6 (Supplementary informa tion S3 (table) ). Together, these advances have enabled the establishment of prominent connections of bioactive sphingolipids to physiology and disease.
Novel metabolic inputs, outputs and extensions.
Studies in the past decade have considerably advanced our understanding of several aspects of sphingolipid metabolism, including the entry of different substrates into sphingolipid metabolic pathways through serine palmitoyltransferase (SPT), the complexity of ceramide species and the exit from sphingolipid metabolism (FIG. 1A) . They have also led to the discovery of previously unsuspected enzymes of sphingolipid metabolism.
Among the important novel findings is the demon stration that other substrates can enter sphingolipid metabolism, in addition to the canonically used serine and palmitate. This finding was initiated by the study of human hereditary sensory and autonomic neuro pathy (HSAN1), which identified mutations in the genes encoding SPTLC1 and SPTLC2, the key subunits of SPT, as the main cause of this disease. Remarkably, these mutations alter the substrate specificity of SPT such that the mutants favour alanine and glycine over serine compared with wildtype forms of the enzyme 7 . This results in the formation of noncanonical metabo lites, the deoxysphingoid and 1deoxymethyl sphin goid bases, respectively, and their acylated ceramides. Lacking the 1hydroxyl (1OH) moiety, both groups result in 'dead end' ceramides that cannot be modified at this position (FIG. 1B) . These mol ecules have since been detected as normal products of SPT, albeit at very low levels. It is currently not known whether they have physio logical functions, but they have been implicated as the mediators of neurotoxicity in HSAN1.
Additionally, the more recently identified SPTLC3 subunit of SPT confers specificity of the enzyme to myristate (over palmitate) as the fatty acid substrate 8 , whereas small subunits of SPT may favour the use of stearate as the fatty acid substrate 9 (FIG. 1) .
Thus, SPT is able to generate a multitude of sphin goid bases. Accordingly, inspired by molecular genetic nomenclature, SPT can be better dubbed Sag/PmsT to indicate its ability to use alanine and glycine as well as myristate and stearate, in addition to the canonical serine and palmitate, respectively.
These variations in the sphingoid backbone are compounded by variations in the acyl groups through the action of distinct ceramide synthases (CerSs) 10, 11 . Longer fatty acids are generated by the action of a family of elongases 12 (FIG. 1A) . Their combined action then allows a remarkable complexity in the structure of ceramides, which is further compounded by the action of additional hydroxylases and desaturases that act on either the sphingoid base or the fatty acyl group. Thus, ceramide is not a single species but should be considered a family of closely related but distinct molecules with emerging distinct functions (many ceramides instead of a single ceramide; see FIG. 1B for nomenclature) 3 . More recent studies have also identified enzymatic activity involved in the ωacylation of ceramides to form threechained ceramides and glycosphingolipids in the skin, which regulate epithelial permeability and skin barrier function (see below). The candidate genes include PNPLA1, which encodes patatin like phospho lipase domaincontaining 1, which has phospholipase and transacylase functions 13 . Ceramides can also be acylated at the 1OH posi tion, and a recent study identified their location in lipid droplets and the pathway leading to their forma tion involving a previously unrecognized ceramide acyl It is convenient to envision sphingolipid metabolism as organized into blocks. Aa | The de novo biosynthetic pathway is initiated in the endoplasmic reticulum by the action of serine palmitoyltransferase (SPT). Sequential reactions lead to the generation of ceramides. Preferential substrates include serine and palmitoyl-CoA, but alanine or glycine and stearate or myristate can also be used. Ab-Ad | Ceramides are then incorporated into various complex sphingolipids (predominantly in the Golgi) through modifications at the 1-hydroxyl position to generate ceramide-1-phosphate (C1P), sphingomyelin or glycoceramides, which in turn serve as the precursors for the various glycosphingolipids. Ae | Ceramides can be acylated to form 1-O-acyl-ceramides. Af | In sphingolipid catabolic pathways, sphingomyelin, C1P and glycosphingolipids are hydrolysed, resulting in the formation of ceramide (see parts b, c and d). Constitutive catabolism occurs in the lysosome. Ceramide can then be deacylated to generate sphingosine, which in turn is phosphorylated to sphingosine-1-phosphate (S1P). Ag | Exit from sphingolipids is initiated by the action of S1P lyase, which cleaves S1P (or dihydroS1P) to a fatty aldehyde and ethanolamine phosphate. The fatty aldehyde undergoes further metabolism, resulting in the formation of palmitoyl-CoA. Ah | The fatty acid (FA) elongation module is an important adjunct component of the sphingolipid pathway, as sphingolipids are the primary lipids with very-long (C22-26) and ultra-long (longer than C26) fatty acyl chains. B | As the precursor of all complex sphingolipids, ceramides constitute a family of closely related molecules that contain a sphingoid base and an amino-linked FA. Different enzymes introduce variations to the basic structure. Fatty acid 2-hydroxylase introduces an OH on the fatty acyl group (variation 1). Sphingolipidδ (4)-desaturase DES1 (DEGS1) introduces a double bond in the 4-5 position of the sphingoid base (variation 2), whereas DEGS2 can introduce an OH on position 4 (not shown). Ceramide synthases introduce fatty acyl groups of distinct chain length (variation 3). SPT can utilize myristate or stearate instead of palmitate, thus introducing variations in the length of the sphingoid backbone (variation 4). SPT can also utilize alanine or glycine, thus introducing variation 5. For easy nomenclature of ceramides, the chain length of the fatty acyl group is indicated (for example, C18 Cer for the N-stearoyl ceramide). More complete nomenclature indicates the sphingoid base length and degree of FA chain desaturation, for example, 18:1C18 ceramide refers to ceramide with canonical sphingosine and stearate in amide linkage. Non-chemical terminology can also be used, for example, dihydroCer refers to ceramides lacking the 4-5 double bond. ELOVLs, elongation of very-long-chain fatty acids proteins. (table) . The full version also contains structures of the sphingolipid species. 4-HPR, fenretinide; ACDase, acid ceramidase; ACER, alkaline ceramidase; aSMase, acid sphingomyelinase; bSMase, bacterial sphingomyelinase; C1P, ceramide-1-phosphate; CERK, ceramide kinase; CerS, ceramide synthase; DEGS1, sphingolipid δ(4)-desaturase DES1; EGF, epidermal growth factor; GALC, galactosylceramidase; GalCer, galactosylceramide; GCS, glucosylceramide synthase; HNSCC, head and neck squamous cell carcinoma; IL-1β, interleukin-1β; LCS, lactosylceramide synthase; NCDase, neutral ceramidase; nSMase, neutral sphingomyelinase; S1P, sphingosine-1-phosphate; SK1, sphingosine kinase 1; SK2, sphingosine kinase 2; SMS, sphingomyelin synthase; TNFα, tumour necrosis factor α.
transferase activity of diacylglycerol Oacyltransferase 1 (DGAT1) and DGAT2 (REF. 14). It was also suggested that DGATs form a complex with CerS and with longchainfattyacid-CoA ligase 5 (ACSL5), which acylates fatty acid substrates required for the action of DGATs. In related studies, the fatty acyl binding protein ACBP has been shown to specifically interact with CerS2 and CerS3 and to channel verylongchain fatty acids to ceramide synthesis 15 . This indicates the important roles of protein complexes in controlling sphingolipid metabolism.
There have also been notable advances in following the fate of the fatty aldehydes as they exit the sphingo lipid pathway. These studies defined the dehydrogen ase ALDH3A2, CoA synthases ACSL1-6, ACSBG1 and ACSVL1 (also known as VLACS), and reductase TSC13 as the enzymes involved in sequential metabo lism of the fatty aldehyde products of sphingolipid clearance 16 (FIG. 1) .
Two novel previously unsuspected enzymes were also identified that add to the complexity of sphingo lipid metabolism. Sphingomyelin synthaserelated (SMSr)
Box 1 | Regulatory inputs and mechanisms of regulation of key enzymes involved in sphingolipid synthesis
Serine palmitoyltransferase (SPT) serves as a critical node for regulating flux through sphingolipid metabolism 158 . Yeast Spt is a large protein complex comprising the main catalytic subunits Lcb1 (also known as Spt1) and Lcb2 (also known as Spt2) and regulatory proteins, including phosphoinositide phosphatase Sac1, the proteins Orm1 and Orm2 and the small subunit Spt-regulating protein Tsc3. Ceramide provides feedback inhibition through dephosphorylation of the Orms in a pathway involving protein phosphatase 2A and its regulatory subunit Cdc55. Orms are further regulated by the action of the serine/ threonine protein kinases Ypk and Pkh, downstream of target of rapamycin complex 2 (TORC2) 42, 159, 160 (see the figure, part a). A wide range of stimuli have been shown to regulate the expression of individual ceramide synthases (CerSs) (refer to tavle 2 in REF. 11 ), and multiple mechanisms have been elucidated in the regulation of the CerSs. NAD-dependent protein deacetylase sirtuin 3, mitochondrial (SIRT3) directly deacetylates several CerSs, promoting CerS activity 161 . CerSs undergo casein kinase 2 (CK2)-dependent phosphorylation, which is suggested to increase CerS activity 162 . CerSs exist as homodimers and heterodimers, and their dimerization in the case of CerS2 and CerS6 is inhibited by binding to Bcl-2-like protein 13 (BCL2L13). This binding inhibits the activities of both synthases and consequently blocks apoptosis Sphingosine kinase 1 (SK1) is activated by growth factors, which, through downstream molecules such as protein kinase C (PKC) and phospholipase D (PLD), activate SK1 through the production of phosphatidic acid. SK1 can also be activated by phosphorylation, for example, through the kinases ERK1 and ERK2. SK1 mRNA is elevated in many cancers (partly owing to transcription activation through hypoxia-inducible factor 1 (HIF1) and HIF2 downstream of hypoxic stress), and it also undergoes translational suppression by microRNAs (mi RNAs) 100 , whereas SK1 protein levels are regulated by proteolysis. In the context of the DNA damage response (DDR), SK1 protein is digested by cathepsin in a p53-dependent mechanism 68 , whereas various pharmacological drugs (such as SKi, PF543 and ABC294640 (REF. 164 )) can induce SK1 proteasomal degradation (see the figure, part c). SK1 activity is also influenced by its affinity for anionic membrane phospholipids and positive membrane curvature; these membrane-curvature-sensing properties of SK1 can be linked to its role in endocytosis 64 . These and additional (see also BOX 2) results disclose complex signalling networks and specific inputs that regulate fluxes through the sphingolipid pathway and/or levels of specific bioactive sphingolipids. was identified as a homologue of SMS but with much reduced activity and with a preference for utilizing phosphatidylethanolamine as a donor of ethano lamine phosphate and thus generating ceramide ethanola mine phosphate rather than sphingomyelin (where phosphatidylcholine serves as the donor of choline phosphate) 17 . Mitochondrial sphingo myelinase was identified as a predominantly mito chondrial neu tral sphingomyelinase, the functions of which are currently unknown 18 . These advances have provided a strong foundation for understanding the biochemistry of sphingolipid metabolism, illustrating its many complexities but also its integration in broader aspects of lipid metabo lism and metabolomics in general. Understanding these enzymes and pathways has also opened up new avenues for the dev el opment of therapeutics targeting sphingolipid related diseases (BOX 3; Supplementary information S3 (table)).
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Compartmentalization of sphingolipids and their metabolism. An important layer in sphingolipid metabo lism is the presence of the multiplicity of enzyme isoforms that are products of distinct genes with speci fic localization, action and/or substrate specificity. For example, there are at least five distinct ceramidases and five distinct sphingomyelinases that localize to the plasma membrane, endoplasmic reticulum (ER), Golgi, nucleus, lysosome, mitochondria or extracellular space. There are also six different CerSs that show distinct prefer ences for fatty acids of various lengths (FIG. 1B) , thus contributing to the remarkable complexity of cera mides (and their downstream anabolic metabolites). While the CerSs appear to localize primarily to the ER, they have also been specifically noted in the nuclear membrane and in mitochondria.
Given that ceramides, sphingomyelins and some of the glycosphingolipids are hydrophobic (glyco sphingolipids with very complex headgroups are much more amphipathic), it is axiomatic that these mol ecules will reside in the compartments where they are gener ated (either hydrolytically or synthetically) unless they are specifically transported. Accordingly, specific transporters have been identified for ceramide (cera mide transfer protein (CERT)), S1P (protein spinster homologue 2 (SPNS2)), C1P (C1P transfer protein (CPTP)), and glucosylceramide (phosphatidylinositol fourphosphate adaptor protein 2 (FAPP2; also known as PH domain containing family A member 8)) (FIG. 2) . Ceramide, as a neutral lipid, appears to readily flip across membrane leaflets, at least in model membranes. This flipping has functional consequences. For exam ple, in the Golgi, ceramide has to flip to serve as the substrate of SMSs in the synthesis of sphingomyelin, as the active site of SMS enzymes faces the lumen of the Golgi 1 . By contrast, synthesis of glucosylceramide from ceramide appears to occur on the cytosolic side of the Golgi. This then necessitates the flipping of glucosyl ceramide in order to serve as a substrate for the syn thesis of higher glycosphingolipids (FIG. 2) . The exact machineries involved in these flipping events are not known. In addition to ceramide, evidence points to the existence of a small pool of sphingomyelin on the cyto solic side of the plasma membrane that may serve as substrates for neutral sphingomyelinase 2 (nSMase2) 19 . In freeze-fracture studies, this pool of sphingomyelin appears to be highly clustered 20 , but it is not known
Box 2 | Mechanisms of regulation of key enzymes of sphingolipid catabolism
Neutral sphingomyelinase 2 (nSMase2) is regulated at the mRNA level by p53 in the context of the DNA damage response (DDR) or by epigenetic mechanisms, including a combination of DNA methylation and histone deacetylation, with histone deacetylation mediating induction by all-trans retinoic acid (ATRA) 70, 157 . It is also regulated by serine phosphorylation promoted by reactive oxygen species (ROS) and tumour necrosis factor (TNF) signalling 165 . Mammalian nSMase has been shown to be allosterically activated by anionic phospholipids and to undergo palmitoylation on at least two distinct sites, which is critical for its association with the plasma membrane 166 (see the figure, part a). Acid sphingomyelinase (aSMase) is encoded by the gene SMPD1, and its mRNA exists as various splice variants, resulting in considerable structural variation in the protein 167 ; regulatory factors of SMPD1 transcription are currently unknown. Translation generates a precursor protein that undergoes glycosylation in the Golgi and can then be targeted to the lysosome or for secretion 127 . The lysosomal form binds tightly to Zn, which is required for enzymatic activity. Several cytokines, including TNF and interleukin-1 (IL-1), can induce the secretion of the enzyme (see the figure, part b) 87 . The activity of secreted aSMase is elusive, considering that the extracellular environment is not favourable for its action (neutral pH, absence of Zn).
Like nSMase, alkaline ceramidase 2 (ACER2) is also a target of p53-mediated activation in the context of the DDR, where it is responsible for the generation of sphingosine 69 . ACER2 is also induced by ATRA and by the synthetic retinoid fenretinide (4-HPR) 168 . By contrast, neutral ceramidase (NCDase) is transcriptionally inhibited by ATRA 169 and by the cytotoxic drug gemcitabine, which induces NCDase proteolysis 170 . The mammalian sphingolipid δ(4)-desaturase DES1 (DEGS1) introduces the critical cis 4-5 double bond into the sphingoid backbone (which imparts apoptotic bioactivity to ceramide), and its inhibition attenuates ceramide and increases dihydroceramide levels, which has been implicated in the induction of autophagy 76 . DEGS1 activity is negatively regulated by ROS and inhibited by the direct action of 4-HPR 171 and by tetrahydrocannabinol (THC) (see the figure, part c) 76 . Nature Reviews | Molecular Cell Biology how the pool is generated (whether by slow flipping of sphingomyelin from the outer leaflet or by mixing of the inner and external leaflets as may occur during endo cytosis and exocytosis). Sphingomyelin is also enriched in a subset of secretory vesicles 21 . The highly bioactive S1P undergoes transporter mediated translocation from inside the cell through the action of SPNS2 (FIG. 2) and several ABC transporters 22 to the extracellular space, where it can access its S1P receptors. Loss of function of SPNS2 leads to the loss of several actions of S1P that appear to require its flipping to reach its receptors.
It is thus becoming clear that the site of action of bioactive lipids and their metabolism is subjected to targeted regulation by mechanisms controlling their transport and membrane leaflet localization.
Structures of enzymes of sphingolipid metabolism and key transporters. Our understanding of the molecular and structural underpinnings of sphingolipid metabo lism has come from highresolution crystal structures of key components of these pathways, including SPT 23 , acid and alkaline sphingomyelinases [24] [25] [26] [27] , acid cerebro sidase 28 , sphingosine kinase 1 (SK1) 29 , neutral cerami dase (NCDase) 30 , nSMase, fatty acid αhydroxylase 31 , the adiponectin receptor (which is proposed to act as a ceramidase) 32 and S1P receptor 1 (S1PR1) 33 , as well as the lipidtransfer proteins CERT (for ceramide) 34 , CPTP (for C1P) 35 and glycolipid transfer protein (GLTP; for lactosylceramide) 36 . Together, these studies have defined the catalytic mechanisms for these enzymes, revealed how they bind and recognize their lipid substrate, aided drug development and allowed us to directly visualize the mechanisms by which sphingolipids can be trans ported between membranes. A common feature of many of these sphingolipid enzymes and transporters is the presence of a large hydrophobic cavity within the protein structure that is used, at least in part, to extract the target lipid from the membrane.
Mechanisms and downstream targets
Our understanding of the mechanisms of action of bioactive sphingolipids is rather sparse. S1P has been the most studied bioactive sphingolipid. S1P is mostly secreted from cells and binds to one of five S1PRs, which are G protein-coupled receptors (GPCRs) 37 . These receptors then mediate all known extracellular actions of S1P through canonical GPCR signalling pathways. S1P can also act intracellularly, where it binds to his tone deacetylases (HDACs), inhibiting their activity and thereby modulating histone acetylation 38 (FIG. 3a) .
Ceramide has been shown to activate protein phos phatases of the PP1 and PP2A families in vitro and in cells, thereby having important roles in the regulation of the cellular phosphoproteome. Several phospho substrates have been defined for this action of cera mide, including serine/threonine protein kinase AKT, protein kinase C and ezrin 39 (FIG. 3a) . More recently, ceramide activated phosphatases have been shown to mediate the effects of palmitate on vascular endothelial growth factor signalling, possibly by interfering with activ ation of endothelial nitric oxide synthase 40 . In addition, cera mide has been shown to regulate the interaction of PP2A with its inhibitor SET (also known as I2PP2A), and this has been implicated in the immuno suppressive functions of regulatory T cells 41 . A strong case has evolved in yeast for the PP2A homologue Sit4 as a target and mediator of many of the actions of yeast ceramides, including regulation of the cell cycle and mito chondrial function 42 . Additional studies impli cate lysosomal cera mide in triggering degradation of Xlinked inhibitor of apoptosis protein (XIAP) in the apoptotic pathway through activ ation of cathep sin B 43 . In a recent study, diverting cera mide to mito chondria was shown to induce apoptosis 44 , supporting an indepen dent role of the mitochondrial ceramide pool, as noted previously 45 . Unfortunately, there is a paucity of results that illuminate the actions of specific species of ceramides.
The mechanisms of action of sphingosine remain poorly defined in spite of a large number of downstream effects (TABLE 1; Supplementary information S2 (table) ) and targets, including protein kinase C. C1P has been shown to interact with several targets, including cyto solic phospholipase A2 (cPLA2) and acid sphingo myelinase (aSMase), and the existence of cell surface receptors for C1P was suggested, but more detailed mechanistic insights for this and other sphingolipid species are lacking thus far.
Cellular functions
The plethora of functions now attributed to bioactive sphingolipids is immense and touches almost all major aspects of cell biology, including roles in cell growth,
Box 3 | Therapeutic targeting of sphingolipids
Pathways of sphingolipid metabolism have become important targets for the development of therapeutics. First, analogues of bioactive sphingolipids are proving to be of use in the treatment of immune and metabolic disorders, as well as cancer. The best developed of these is FTY720, an analogue of sphingoid bases, which has been used in clinical medicine for the treatment of multiple sclerosis. FTY720 is converted to its phosphate derivative by the action of sphingosine kinase 2 (SK2), and in this form, FTY720-Pi modulates immune cell kinetics (primarily the egress of lymphoid cells from lymphoid organs). Myriocin (ISP1), an analogue of sphingosine that functions as a potent inhibitor of serine palmitoyltransferase (SPT), has been evaluated in vivo as a metabolic modulator with favourable effects in diabetes and in metabolic syndrome. Short-chain analogues of ceramide, such as C6 ceramide, are being formulated in nano-liposomal particles for use in leukaemia.
Many of the enzymes of sphingolipid metabolism have themselves become targets for therapeutics. As mentioned above, SPT has been targeted in animal studies by myriocin. SK1 has been studied extensively, and high-potency (and high-specificity) inhibitors are now available 172, 173 . However, clear indications for use have yet to be determined 174 .
Inhibitors of acid ceramidase are the subject of intensive development 175 .
In the case of sphingosine-1-phosphate (S1P), its G protein-coupled receptors are receiving increasing attention as therapeutic targets. Ozanimod, an agonist of S1P receptor 1 (S1PR1) and S1PR5, has shown modest effects in human ulcerative colitis 176 . In addition, a monoclonal antibody against S1P has been developed and has shown moderate responses in a phase II trial in patients with metastatic renal cancer 177 . Notably, sphingolipids are present not only in mammalian cells but also in certain parasites, including fungi and protozoa. Some of the enzymes involved in their metabolism have no direct human counterparts, and thus they can serve as targets for the development of anti-parasitic drugs 178 .
Globosides
A subtype of sphingolipids with a ceramide associated with at least two sugars, but no sialic acid.
Diauxic shift
The shift in growth from rapid fermentative to aerobic glycolysis.
the cell cycle, cell death, cell senescence, inflamma tion, immune responses, cell adhesion and migration, angio genesis, nutrient uptake, metabolism, responses to stress stimuli and autophagy (TABLE 1; Supplemen  tary information S2 (table) ). The studies of sphingo lipid functions have been propelled by the increasing preci sion of tools such as RNA silencing and, more recently, CRISPRmediated deletion of specific genes encoding sphingolipid enzymes, as well as by the use of model organisms. There have been several inform ative reviews on the biological functions of bioactive sphingo lipids 1, 39, 46, 47 . Here, we focus on some of the more developed aspects of sphingolipid biology that are sup ported by multiple lines of investigation and often come from several laboratories.
Insights from yeast studies. Studies in Saccharomyces cerevisiae have firmly established multiple roles for sphingolipids in the adaptive responses to heat stress, which increases metabolic flux through the de novo pathway, most likely owing to increased uptake of serine. The sequentially generated sphingoid bases, sphingoid base phosphates and ceramides have been implicated in mediating key responses to elevated temperatures, including transient cell cycle arrest, arrest in translation and sequestration of mRNA and regulation of nutrient permeases 42, 48, 49 . In a combined 'omic' approach, specific ceramides were implicated in specific transcriptional responses, regulating the expression of genes involved in iron transport, acid sensitivity and RNA metabolism, illustrating the complexity of ceramide functions in yeast 48 . Cell cycle checkpoints mediated by mitosis inhib itor protein kinase Swe1 were attributed to ceramides, in particular C18:1 ceramide 50, 51 . Additional functions for yeast ceramides include regulation of the diauxic shift and mitochondrial function, the DNA damage response and regulation of responses to reactive oxygen species 42 .
Cell adhesion and migration.
A critical role is emerging for bioactive sphingolipids in the regulation of cell adhe sion, migration and invasion. Recent studies implicated SK1 and SK2 (the enzyme producing S1P) in filopodia formation, cell migration and invasion in response to different stimuli, including epidermal growth factor, in a mechanism that involves induction of phosphoryl ation of the ezrin, radixin and moesin (ERM) family protein ezrin 52 , which is known for its function in regu lating cellular motility 53 . The mechanism involves the activation of S1PR2 and implicates the transporting functions of SPNS2 (REF. 52 ). Remarkably, a recent study using a genomewide in vivo screen in mice identified SPNS2 as a prominent promoter of metastasis 54 . Also of interest, S1pr2knockout mice are deaf 55 , similarly to mice deficient for another ERM protein, radixin 56 , as well as to Spns2knockout mice 57 , suggesting a common pathway involving these three components. Reciprocally, ezrin can be dephosphorylated in a mech anism involving ceramidemediated activation of the protein phosphatase PP1α 58 . These studies illustrate the mechanistic and functional crosstalk between bioactive sphingolipids (FIG. 3a) .
Formation of membrane domains, exosomes and endosomes.
Sphingolipid metabolism has been shown to affect membrane organization and dynamics, as well as vesicular transport (FIG. 3b) .
Substantial literature supports the existence of special ized membrane domains, especially in the plasma membrane, which are enriched in specific lipid species, including sphingolipids (with an important contrib ution of ceramides). Although the precise nature and function of these domains, which also include rafts, are still not clear, they could have important roles in regulating the function of membrane receptors. Thus, ceramides could influence cell signalling by contrib uting to (and potentially promoting) the formation of membrane domains 59 . It is now becoming clear that the cellular actions of bioactive sphingolipids are 'local'. Therefore, the site of production of these lipids is critical, and it is determined by the location of the specific enzymes involved in the regulatory pathways. For details of the compartmentalization of these processes, please refer to box 1 in REF. 1 . Moreover, the metabolic and cellular functions of bioactive lipids are further controlled by specific translocases and lipid transport proteins. A strong case can now be made that ceramides (Cers) generated in the endoplasmic reticulum (ER) can reach the Golgi either by a vesicular route, where they are coupled to the synthesis of glucosylceramide, or by specific translocation via the action of ceramide transfer protein (CERT), which couples ceramides to the synthesis of sphingomyelin (SM) 179 . Likewise, the transfer protein phosphatidylinositol-four-phosphate adaptor protein 2 (FAPP2) can transfer glucosylceramide (GlcCer) between Golgi networks and couple it specifically to the synthesis of globosides (globo series of neutral glycosphingolipids) as opposed to the anionic ganglio series 180 . Ceramide-1-phosphate (C1P) is the target of the non-vesicular translocation activity of C1P transfer protein (CPTP), which is involved in transferring it from the Golgi to other compartments such as the plasma membrane 35 . Protein spinster homologue 2 (SPNS2) flips sphingosine-1-phosphate (S1P) across the plasma membrane to deliver it to exocytoplasmic leaflets, where it can access its receptors (a subfamily of G protein-coupled receptors (GPCRs)) 22 . VAP, vesicle-associated membrane protein-associated protein. Suggesting the role of sphingolipids in membrane dynamics and signalling more broadly, a landmark study identified a role for nSMase and the resultant ceramide in the formation and secretion of exosomes, a specific subtype of secreted vesicles that have been implicated in cell-cell signalling and communication 60 . Subsequently, several studies have disclosed that inhib ition of nSMase2 can interfere with the cargo composi tion of these vesicles, including microRNA (miRNA) 61 , prion proteins 62 and other cargo proteins with impor tant roles in neuro development and neurodegeneration. However, inhib ition of SMS2 promotes exosome secre tion by neurons and could be linked to the clearance of the neurotoxic amyloidβ by microglia 63 , suggesting thera peutic possibili ties in Alzheimer disease by modulating the metabolism of sphingolipids.
Furthermore, SK1 was implicated in endosome regu lation (FIG. 3b) , whereby knockdown of SK1 led to defects in endocytic recycling, suggesting an important role for S1P in endocytic membrane trafficking that is likely independent of its role in signalling through S1PRs 64 . Sphingolipids also appear to be involved in the inter nalization of viruses, as illustrated by the implication of SMS2 in the fusion of the HIV viral envelope with the host cell plasma membrane 65 . It was also demonstrated that a specific species of sphingomyelin, C18 sphingomyelin, is recognized by p24, a component of the coatomer protein COPI comprising secretion machinery, and this interaction is important for vesicular trafficking 66 . This example highlights the importance of the distinct cellular roles of molecular subspecies of sphingolipids mentioned above. Nature Reviews | Molecular Cell Biology . S1P has to flip extra-cytosolically (with the involvement of protein spinster homologue 2 (SPNS2)) in order to interact with one (or more) of its five receptors (S1P receptor 1-5 (S1PR1-5)). S1P can also be released from the plasma membrane into the blood, and it is present in relatively high levels in the circulation. S1PRs transmit signals to key downstream targets such as serine/threonine protein kinase AKT, RHO and the Ras-ERK and tyrosine protein kinase JAK-signal transducer and activator of transcription (STAT) pathways. Signalling through S1PRs also has other cellular targets. For example, S1PR actions result in robust phosphorylation of ezrin, which affects actin dynamics, promoting filopodia formation and cell migration (including cancer cell invasion). S1P also has nuclear actions -it binds and inhibits histone deacetylases (HDACs), leading to alterations in protein (histone) acetylation 38 . Ceramides (Cers) can be formed in several compartments. At the plasma membrane, ceramide generation from the action of sphingomyelinases (SMases) results in activation of protein phosphatase PP1Cα, which induces dephosphorylation of its substrates, including ezrin.
Ceramide formed metabolically from the supply of palmitate can activate PP2A phosphatases to result in dephosphorylation and inactivation of AKT. Activation of PP2A by ceramide also occurs in the context of apoptosis. In this case, the pro-apoptotic protein Bcl-2 homologous antagonist/ killer (BAK) promotes ceramide synthesis (through activation of ceramide synthase (CerS)), followed by PP2A activation and dephosphorylation and inactivation of anti-apoptotic BCL-2 proteins. In addition, mitochondrial ceramide was shown to promote the activity of the apoptosis regulator BAX, a pro-apoptotic protein. b | Bioactive lipids are increasingly appreciated to regulate membrane dynamics. Formation of ceramide at the plasma membrane by acid SMase (aSMase) has been shown to induce formation of distinct membrane domains that affect endocytosis and receptor signalling (for example, tumour necrosis factor receptor superfamily member 6 (FAS)) signalling. Neutral SMase2 (nSMase) and ceramide have been implicated in exocytosis, and SK1 and S1P have been implicated in endocytosis. c | Egress of lymphocytes from lymphoid tissues to the blood is controlled by a gradient of S1P (high in blood and low in lymphoid tissue). The response to this gradient is primarily driven by S1PRs, especially S1PR1. The clinical compound FTY720 is converted to the active FTY720 phosphate through phosphorylation mediated by SK2 to suppress S1PR1 function and therefore lymphoid egress. ApoM, apolipoprotein M; ER, endoplasmic reticulum; HDL, high-density lipoprotein; TRK, tyrosine kinase receptor.
ER stress
Endoplasmic reticulum (ER) dysfunction due to stress stimuli that result in increased accumulation of misfolded proteins in the ER.
Necroptosis
A regulated form of necrotic cell death associated with immune and inflammatory responses.
Multiple sclerosis
A degenerative disease of the nervous system associated with a loss of myelination (covering) of axonal sheaths.
T cell egress
Lymphocyte migration from the thymus and lymph nodes into the bloodstream.
Finally, the existence of an intricate crosstalk between sphingolipid metabolism and membrane dynamics has been illustrated by cellular studies, demonstrating that a finely tuned mechanism involving the combined action of CERT, SMSs and protein kinase D regulates both sphingomyelin levels and vesicular trafficking from the Golgi 67 .
Implications in DNA damage response. Early stud ies had demonstrated that many cytotoxic and DNAdamaging agents induced profound changes in the levels of sphingolipids, in particular leading to increased levels of ceramide. Accordingly, enzyme centric studies identi fied SK1, alkaline ceramidase 2 (ACER2), nSMase2 and CerSs as specific players in the DNA damage response (DDR) (see also BOXES 1,2). SK1 protein levels are subjected to p53induced degrad ation, and this has been implicated in regulating cell survival and inflammatory responses. This connection was supported by an in vivo study demonstrating that Sk1 (also known as Sphk1) knockout protected mice from thymic lymphomas induced by the loss of p53 (REF. 68 ). By contrast, ACER2 mRNA levels are induced by p53, and this protects cells with wildtype p53 from ceramide mediated cell death 69 . Similarly, nSMase2 is induced during the DDR and appears to have a role in cell cycle regulation 70 . An analogous role has been shown for the S. cerevisiae protein Isc1 (a homologue of nSMase2) 50 . Additional studies have implicated CerSs as mediators of cytotoxic responses of cancer cells to various chemo therapeutic and stress agents (reviewed in REF. 11 ; see also BOX 1) .
Roles in senescence, ageing, autophagy and apoptosis.
In yeast, lag1 and lac1 were the first genes identified as important determinants of lifespan. Eventually, it was determined that the products of these genes function as CerSs 71 . In parallel, mammalian cell studies had impli cated ceramide as a key regulator of cell senescence 5 . More recently, the three CerSs in Caenorhabditis elegans were demonstrated to regulate lifespan, interestingly in both directions depending on the enzyme. This study highlights the complexities of sphingolipid metabolism, showing that the variation in ceramide composition determined by the activity of the different CerSs can greatly affect animal lifespan; these different effects were further linked to the modulation of the response to dietary restriction and activation of autophagy 72 . Along similar lines, haplotype analysis of human longevity associated genes identified CERS1 as a key gene enhancing exceptional survival (those living into the 10th decade) 73 . Autophagy has recently emerged as a highly regu lated process in which sphingolipids are importantly involved. Ceramides regulate both cell survival and cell deathlinked autophagy by regulating nutrient transporters, ER stress and mitophagy (reviewed in REF. 74 ). Accumulation of dihydroceramide by inhibit ing the desaturation of cera mides (see BOX 2) has been implicated in regulating autophagy 75 , in particular autophagyinduced death of cancer cells 76 .
Another highly regulated process in which bioactive sphingolipids have emerged as key players is cell death. Ceramide has been identified as a key regulator of apop tosis 77 , and this cellular activity of ceramide has since been extensively studied (reviewed in REF. 39) (FIG. 3a) . Of note, several enzymes that regulate the generation of ceramides, including CerSs, SMases, SK1 and SK2, are distributed in different cellular compartments such as mitochondria, the plasma membrane or lysosomes (Supplementary information S3 (table) ), which can influence distinct mechanisms of cell death (apop tosis versus necroptosis) depending on the activity of these enzymes 44, 78 .
Roles in (patho)physiology
An increasing appreciation of the roles of sphingo lipids in organismal physiology and pathophysiology is driven by the translation of basic cell studies to animal and human processes, which in turn has been greatly facili tated by the development of knockout mice for a majority of enzymes of sphingolipid metabolism (Supplemen tary information S3 (table) ). Equally as gratifying has been the appreciation of critical roles of sphingolipids from studies beyond the sphingolipid domain (for exam ple, an unbiased screen uncovered the role of SPNS2 in metastasis 54 ). Here, we discuss a few beststudied examples of how sphingolipids affect organismal biology.
Immune and inflammatory functions.
A strong case for S1P in the function of the immune system has been established 46 (FIG. 3c) . This has found a direct application in the treatment of multiple sclerosis with FTY720 (fingo limod), a sphingoid base analogue 79 . Briefly, T cell egress is controlled by a gradient of S1P between the lymph and plasma 80 that is established by the secretion of S1P from haematopoietic and endothelial cells into plasma 81 . S1PR1 expressed on lymphocytes then responds to this gradient, leading to the migration of lymphocytes from lymphoid tissues into the circulation 82 . This process is inhibited by FTY720, which is converted by SK2 into FTY720 phosphate, which then acts to tonically suppress S1PR1, thus leading to the sequestration of T cells in the thymus and lymph nodes. Consistent with these findings, phospholipid phosphatase 3 (LPP3), an S1P phosphatase that hydrolyses S1P, was found to promote lymphocyte egress, presumably by decreas ing S1P levels in target organs and thus maintaining a blood (high)-tissue (low) S1P gradient 83 . In addition, a speci fic pool of S1P bound to highdensity lipo protein (HDL) has been shown to regulate lymphopoiesis and neuro inflammation not only by regulating delivery of S1P to the blood but also by modulating its receptor signalling pathways 84 . A connection has also emerged between bioactive sphingolipids and the cPLA2-cyclooxygenase 2 (COX2) pathway, which generates bioactive prostaglandins. Studies have implicated SK1 and S1P in regulating the expression of COX2, although the mechanisms remain unclear. Additionally, C1P and the enzyme that forms it, ceramide kinase, have been implicated in the direct activ ation of cPLA2 in response to cytokines 85 . These results suggest an important role for C1P and S1P in inflammatory responses. However, it was shown that deletion of SK1 from macrophages is not required for inflammatory responses but did sensitize these cells to autophagyinduced death 86 . Ongoing studies also suggest roles for aSMase in sustaining inflammation through the production of inflammatory cytokines, especially interleukin6 (IL6) and CCchemokine ligand 5 (CCL5) in response to the action of tumour necrosis factor (TNF) and IL1 (REF. 87 ). Clinically, levels of serum aSMase have been shown to predict mortality in patients in intensive care units at risk of developing systemic inflammation 88 , an effect most likely related to the induction of aSMase release by TNF. (table) ). On the one hand, S1P has been impli cated in tumour cell survival, cancer inflammatory pathways, angiogenesis, resistance to chemotherapy and cancer cell invasion. On the other hand, ceramides have been implicated in cancer cell apoptosis, growth arrest, mediating sensitivity to chemotherapeutics and senes cence 89, 90 . Here, we discuss some of the more mature findings implicating sphingolipids in specific cancers.
A strong case has evolved for a role for SK1 in colon cancer, especially colitisassociated cancer (CAC). These studies were prompted by the finding that SK1 is involved in the regulation of COX2 and cell inflamma tory responses 91 . Human colon cancer showed upregula tion of SK1 in 89% of cases, and this correlated with the high levels of COX2. Higher levels of SK1 in colon cancer in an Asian population correlated with advanced stage and predicted increased mortality 92 . Sk1knockout mice were partly resistant to chemically induced colitis, and they showed significant attenuation of colon cancer in a model of CAC 93 . Mechanistic studies defined a role for SK1 in mediating the induction of COX2 in vivo 93 as well as in the regulation of the expression of signal transducer and activator of transcription 3 (STAT3), which is a key transducer of proinflammatory signals from several types of plasma membrane receptors 94 . Moreover, loss of SK1 also decreased the growth of adenomas in a mouse model of intestinal cancer 95 . In addition to the increase in SK1, S1P lyase is downregulated in colon cancer tissues, further promoting S1P signalling 96 . Interestingly, knock out of SK2 resulted in reciprocal increases in SK1, which were implicated in increased risk of colon cancer in mice 94 . In line with the studies presented above, target ing SK1 with inhibitors showed activity against colon cancer in xenografts 97 and CAC mouse models 98 . Thus, these studies confirm that the S1P pathway contributes to colon carcinogenesis, likely by regulating synthesis of prostaglandins and other inflammatory mediators.
Interestingly, and in contrast to S1P, ceramide levels have been shown to be reduced in human colon cancer, consistent with the overall opposing functions of these two lipid mediators (FIG. 1A) . As such, deletion of NCDase, which augments ceramide levels, protected mice from the development of colon cancer in a carcinogeninduced model of colon cancer 99 . However, it should be noted that the involvement of NCDase appears to be distinct from the role of SK1 in CAC.
The SK1-S1P pathway has also been implicated in several other cancers, including glioblastoma, head and neck cancer, renal cancer and several leukaemias 100 . Notably, the cancerpromoting roles of this pathway extend beyond actions on cancer cells (such as protec tion from apoptosis). For example, S1P has emerged as a key regulator of angiogenesis with widely impor tant implications in vascular biology and cancer [100] [101] [102] , and SK1 is induced in many cancers in response to hypoxia and in renal cell carcinoma with mutations in the von Hippel-Lindau (VHL) gene. The resultant paracrine increases in S1P in hypoxia have been implicated in angiogenesis and lymphangiogenesis 103 . Acid ceramidase (ACDase) is another enzyme that has received considerable attention in the context of cancer biology, in particular in the development of therapeu tics 104, 105 . The levels of this enzyme are increased in several cancers, including head and neck cancer, melanoma and prostate cancer, and correlate with the advanced patho logy of these tumour types. ACDase serves to attenuate levels of ceramide, and inhibitors of ACDase sensitize cancer cells to chemotherapy and radiotherapy in cell cul ture and in xenografts 104 . A newly developed and potent inhibitor of ACDase synergized with several chemo therapeutics to induce melanoma cell death 106 . Higher levels of ACDase correlate with increased aggressive ness of melanoma, whereas the expression of aSMase, which promotes ceramide generation, is inversely corre lated with tumour stage 107 , indicating a strong correla tion between low levels of ceramide and advanced stages of disease in many cancers. However, evaluation of the expression of ACDase in breast cancer showed that it is expressed at higher levels in lowrisk, luminal A type breast cancer, and high expression was associated with better prognosis 108 . Therefore, whereas ACDase appears to, at least in part, drive malignancy in head and neck cancer, melanoma and prostate cancer, it has rather protective functions in breast cancer.
As another example, plateletderived aSMase was implicated in promoting cell adhesion and metasta sis of melanoma 109 . In addition, aSMase in endothelial cells has been proposed to have a key role in tumour angiogenesis, as it has been shown to mediate sensitiv ity to antiangiogenic therapy by elevating the levels of ceramide 110 . Exciting studies are also pointing towards the usability of sphingolipid levels and the activity of their metabolic enzymes as biomarkers in cancer. A recent metabolo mic profiling of pancreatic adenocarcinoma identified changes in sphingolipid levels, including elevation of sphingomyelin, as a dominant component and determin ant of a 'lipogenic' subtype defined by the investigators as showing distinct metabolism of lipids 111 . Increases in plasma ceramide levels have been shown to be predictive of the response of metastatic tumours to radiation ther apy 112 . Along similar lines, CerS6 emerged as a strong predictor of survival in human colon cancer 113 .
These results indicate that specific perturbations in one or more pathways of bioactive sphingolipids can affect various key components of cancer development (for example, growth, migration, angiogenesis and immune signalling) and responses to therapies. These perturba tions are emerging as cancerspecific, possibly due to the distinct functions of various enzymes in different tissues and under distinct conditions. Thus, these roles need to be appreciated in this tissuespecific context. Metabolic functions and connections to diabetes and the cardiovascular system. A strong case is emerging for a role for ceramides in regulating metabolic functions, and changes in levels of ceramide species have been implicated in various metabolic syndromes, such as fatty liver disease 114 , obesity 115 and insulin resistance 47, 116 . Cell and in vivo studies have demonstrated that increased ceramide levels result in attenuation of insulin action, most likely via inhibition of AKT (FIG. 3a) . This inhib itory pathway appears to be particularly engaged by the increased supply of palmitic acid, which can drive ceramide synthesis directly as a precursor substrate. Increased ceramide synthesis in the context of insulin resistance was also shown to be driven by inflammatory agents (for example, agonists of Tolllike receptors, TNF and interleukins) 47 . Attenuation of ceramide generation in vivo, by use of inhibitors of SPT or dihydroceramide desaturase or mice deficient in these enzymes, improves insulin signalling and glucose and lipid metabolism in diabetes and alleviates obesityassociated metabolic changes and cardiac dysfunction 117, 118 . Furthermore, mice deficient in CerS6 are protected from weight gain and glucose intolerance 119 induced by a highfat diet, and overexpression of ACDase led to a reduction of hepatic steatosis 120 . Similarly to cera mide, other sphingolipids, including sphingomyelin and glucosylceramide, have also been shown to inhibit insulin action 121 . Accordingly, Sgms2knockout mice, in which sphingomyelin levels are reduced, showed increased sensitivity to insulin and resistance to obesity induced by a highfat diet 122 . Notably, these effects were observed despite an associ ated increase in the levels of ceramide, suggesting that ceramide is not the primary mediator of insulin signal ling inhibition or that in the context of Sgms2 knockout, the elevated ceramide is diverted to other pathways. Interestingly, different metabolic functions were found for SGMS1, deletion of which caused decreased insulin secretion and induced oxidative stress in white adipose tissue, leading to the destruction and dysfunction of white adipocytes 123 . Metabolic roles of S1P are also emerging. In mice, deletion of the gene encoding S1P phosphatase 2 (Sgpp2), which degrades S1P, was associated with basal ER stress in pancreatic βcells and increased sensitivity to a highfat diet 124 . Consistent with these results, dele tion of the gene encoding SK1 was shown to protect against dietinduced hepatic steatosis 125 . In support of the role of ER stress in mediating these metabolic effects of S1P, cellbased studies have demonstrated involve ment of S1P signalling in regulating heat shock proteins, the unfolded protein response in the ER and ER stress 126 . Sphingolipids, and especially ceramide and sphin gosine, have been implicated in vascular disease, includ ing atherosclerosis and ischaemic injury. Increased activity of aSMase and levels of ceramides have been linked to atherogenesis; the mechanism possibly involves secreted aSMase that may act on lipoproteinassociated sphingo myelin to convert it to ceramide 127 . Accordingly, attenu ation of aSMase was demonstrated to act protectively against retinal ischaemic injury in mice 128 . In support of the general impact of sphingolipid metabolism on vas culature, inhibition of de novo synthesis of sphingolipids with myriocin attenuated myocardial reperfusion injury 129 . From a clinical perspective, a very compelling case is developing for the utility of measuring serum sphingo lipids (mostly ceramides) as indicators of metabolic disorders and atherosclerotic cardiovascular diseases. For example, plasma levels of C24 and C26 ceramides as well as deoxyC24 ceramide have been associated with diabetic neuropathy 130 . Elevated C18:0 and C18:1 ceramides were also shown to be strong predictors of major adverse cardiovascular effects in healthy sub jects 131 . Similarly, C18:1 ceramide was found to be a key predictor of high amounts of necrosis after coronary angiography procedures 132 . Another study identified C24:1 ceramide and sphingomyelin as being strongly associated with cardiovascular mortality 133 . Higher levels of plasma C22:0 and C24:0 ceramides have also been shown to predict less improvement in verbal memory in response to exercise in patients with coronary artery disease in which these skills decline 134 . In addition to the use of ceramides as biomarkers, serum S1P levels inversely corre lated with atherosclerotic disease 135 , whereas deoxy sphingolipids have been shown to serve as a biomarker in diabetes progression 136 .
Sphingolipids as drivers of neurodevelopment and neuro degeneration. Genetic defects in various enzymes of sphingolipid metabolism reveal important roles for these enzymes in brain development and health (reviewed in REF. 6 ). These compelling conclusions have come from converging studies using both mouse knock outs and genetic tracing of human disease. These include defects in fatty acid 2hydroxylase (FA2H) 137 , ACER3 (REF. 138 ), SPTSSB (a small subunit of SPT) 139 , CerS1 (REF. 140 ) and CerS2 (REFS 141, 142) (Supplementary  information S3 (table) ). These recent studies suggest that key sphingolipid metabolites are critical for normal brain development and function. In most cases, the sphingolipid species that may cause neural dysfunc tion are not known. However, in a recent study of Cers1 knockout, neuronal production of C18:1 ceramides and other sphingolipids was found to be impaired, leading to the accumulation of sphingoid bases and neurodegener ation. These effects could be corrected by overexpression of CerS2 (REF. 143 ), suggesting that sphingoid bases are the candidate mediators of neuronal injury.
In addition, deficiency of nSMase2 was shown to decrease pathology associated with Alzheimer disease in mice 144 , whereas deletion of Asah2, which encodes NCDase, attenuated brain damage associated with traumatic brain injury 145 .
Insulin resistance
A state in which cells, tissues or organisms fail to respond normally to insulin.
Glucose intolerance
Also known as impaired glucose tolerance. A pre-diabetic state involving hyperglycaemia and usually poor responsiveness to insulin.
Hepatic steatosis
Condition associated with non-alcoholic fatty liver disease with increased accumulation of fat in liver cells, usually in the form of triglycerides.
Ischaemic injury
Tissue and cell injury that results from a decrease in or interruption of the blood supply.
Reperfusion injury
Injury or damage to tissues resulting from the reoxygenation of previously ischaemic tissues.
Diabetic neuropathy
Dysfunction of the peripheral and autonomic nervous system that arises from long-standing diabetes.
Coronary angiography
An invasive procedure using dyes in the bloodstream to visualize the coronary circulation using radiography.
Taken together, these studies begin to define sev eral causal roles for sphingolipids in normal brain functions and as mediators of neuronal damage and neurodegenerative disorders.
Skin-specific sphingolipids and their functions. Skin is characterized by the presence of unusual sphingo lipids based on ultralong fatty acyl chains as well as fatty acyl groups linked on the ωend of the Nlinked fatty acids (thereby generating a threechain rather than a twochain molecule). Loss of function of several enzymes involved in sphingolipid metabolism leads to various forms of skin and hair defects that are often fatal -loss of CerS3 (REF. 146 ), elongation of very longchain fatty acids protein 4 (ELOVL4), CYP4F22 (the ωhydroxylase) 147 , glucosylceramide synthase (UGCG) 148 or PNPLA1 (REF. 13 ) leads to defects in skin epithelium organization and function, whereas loss of ELOVL3 and ELOVL4 (REFS 149, 150) , CerS4 (REF. 151) or ACER1 (REF. 152 ) results in hair loss phenotypes. At least for some of these enzymes, the defects resulting from their deficiency appear to be mechanical in nature, in that the skin fails to form an impermeable barrier owing to the loss of its specialized, longchain ceramides.
Tissue-specific sphingolipid metabolism in bone and cartilage development. A strong case has been made for a role for nSMase2 in bone and cartilage develop ment. Knockout of nSMase2 resulted in a stunted growth pheno type of the mice 153 . Independently, it was shown that fro/fro mice, a model of osteogenesis imperfecta, carry an inactivating truncation in Smpd3 (encoding nSMase2). Subsequent studies have shown that the defects in development in bone and cartilage are likely due to tissueautonomous and/or cellautonomous actions of nSMase2 (REF. 154 ). Accordingly, in chondro cytes, nSMase2 was demonstrated to be a downstream target for bone morphogenetic protein 2 (REF. 155 ) and for alltrans retinoic acid (ATRA) 156, 157 , key regulators of bone and cartilage development.
Conclusions and perspectives
The extent to which mammalian cells have evolved the network of bioactive sphingolipids to control many critical cellular and organismal functions is remarkable. The complexity of this network makes sphingolipids extremely difficult to study, particularly in the con text of the entire organism, where specific functions in individ ual tissues and organs crosstalk and converge. Much has been accomplished in terms of defining the basic biochemical components and tools for study ing and modulating pathways in this network and in advancing our understanding of the multifaceted roles of sphingolipid species. However, much remains to be achieved. In partic ular, molecular and biochemical mechanisms that regulate the many enzymes of sphingo lipid metabo lism and the flux through the system, with its many nodes and interconnections and compartments, require further investigation and refining. Equally important, there is a compelling need to understand the mechanisms of actions of the many ceramide species and sphingoid bases, as well as other emerging bio active sphingolipids. Only such a level of understand ing, considering individ ual sphingolipid species and their changes in different physiological and pathological contexts, will allow a precise delineation of the specific roles and functions of these pathways and how they fit in the larger universe of cell regulation and biology.
